YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The United States market has seen a positive trend, rising 1.2% over the last week and 27% over the past year, with earnings projected to grow by 17% annually in the coming years. In this context of robust market performance, growth compan…
The United States market has shown robust performance, climbing 1.2% in the last week and rising 27% over the past year, with earnings projected to grow by 17% annually in the coming years. In such a thriving environment, growth companies…
(RTTNews) - Biotech stocks are showing strong pre-market moves this Tuesday, hinting at possible breakout setups. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. In the Green - Premarket Gainers On Tuesd…
The United States market has shown robust performance, climbing 1.8% in the last 7 days and up 28% over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, growth companies with high insider owner…
Over the last 7 days, the United States market has risen by 1.3%, contributing to a robust 28% increase over the past year, with earnings expected to grow by 17% annually. In this thriving environment, growth companies with high insider ow…
The United States market has experienced a positive trend, with a 1.3% increase over the last week and a substantial 28% rise over the past year, while earnings are projected to grow by 17% annually. In this environment, growth companies w…
Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on driving innovation for human health Will assist with listeria oncology pipeline prioritization, co…
Senior leadership roles at Guardant Health, Genentech and Pfizer Regulatory, clinical and commercial expertise in therapeutics and biomarkers Will assist with osteosarcoma regulatory advice and oncology pipeline prioritization New York, Ne…
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing…
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – Biopharma M&A is entering a fever pitch, with precision oncology investments alone exploding to…
* OS Therapies (OSTX [https://seekingalpha.com/symbol/OSTX]) on Thursday announced [https://seekingalpha.com/pr/20315181-os-therapies-to-spinoff-os-animal-health-into-standalone-public-company]its intent to spin off OS Animal Health into a…
Successful preliminary discussion with NYSE representatives and potential investors OS Therapies shareholders to receive direct equity participation in new listing 'Shelter Me: Cancer Pioneers' film featuring canine and human patients trea…
* OS Therapies press release [https://seekingalpha.com/pr/20309223-os-therapies-reports-third-quarter-2025-financial-results-and-provides-business-update] (OSTX [https://seekingalpha.com/symbol/OSTX]): Q3 GAAP EPS of -$0.21 misses by $0.08…
As the U.S. market experiences a surge in optimism following news of a potential deal to end the government shutdown, major indexes like the Nasdaq and S&P 500 have rebounded significantly, reflecting renewed investor confidence. In such d…
* OS Therapies press release [https://seekingalpha.com/pr/20204527-os-therapies-reports-second-quarter-2025-financial-results-and-provides-business-update] (NYSE:OSTX [https://seekingalpha.com/symbol/OSTX]): Q2 Reported final EFS data (35%…
* OS Therapies (NYSE:OSTX [https://seekingalpha.com/symbol/OSTX]) filed $100M mixed securities shelf. * Filing [https://seekingalpha.com/filing/10286300] MORE ON OS THERAPIES * Seeking Alpha’s Quant Rating on OS Therapies [https://seekinga…
As the U.S. stock market faces volatility due to recent tariff announcements and a weaker-than-expected jobs report, investors are re-evaluating their strategies amidst these economic uncertainties. In such an environment, growth companies…
As July 2025 comes to a close, the U.S. stock market has experienced a mixed performance with major indexes like the S&P 500 and Nasdaq posting gains for the third consecutive month, despite recent volatility driven by fluctuating tech ear…
As the U.S. market navigates a wave of corporate earnings reports and anticipates key economic data releases, indices like the S&P 500 and Nasdaq have recently retreated from their record highs, reflecting a cautious investor sentiment ami…
The United States market has shown robust performance, climbing 1.5% in the last week and achieving an 18% increase over the past year, with earnings projected to grow by 15% annually. In this thriving environment, growth companies with hi…
Current holders of five-year warrants with a current exercise price of $1.12 per share issued in connection with PIPE transaction initially closed on December 31, 2024 (Old Warrants) offered opportunity to exercise Old Warrants now to rece…
(RTTNews) - OS Therapies Inc. (OSTX), a clinical-stage biotech company focused on cancer immunotherapies and antibody-drug conjugates, has partnered with EVERSANA to support the U.S. commercialization of OST-HER2. This novel treatment targ…